A large, decentralised register-based program in Sweden has enrolled over 2,000 adults with recent-onset type 2 diabetes, comparing dapagliflozin with metformin in routine primary care. Baseline data highlight that even within 4 years of diagnosis, signs of nephropathy, retinopathy, or foot-at-risk already affect a notable minority, alongside high rates of hypertension and dyslipidaemia. Interim event monitoring over roughly 19 months shows composite complication rates driven predominantly by microvascular outcomes , whereas major cardiovascular events and death remain relatively infrequent in this timeframe.
These findings underline how quickly microvascular disease can accumulate despite contemporary risk-factor management in so-called “ early ” diabetes. Consider how proactively you screen and intervene for microvascular damage in newly diagnosed type 2 diabetes, beyond focusing on…
